Oncology Central

Combination of PARP and PD-1 inhibition shows promise for the treatment of advanced solid tumors

A Phase I trial using a combination of immunotherapy drugs has demonstrated promise for the treatment of advanced solid tumors.

Described in an abstract that was presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (CA, USA, 25-27 January), the Phase I trial was led by Michael Friedlander (Prince of Wales Hospital, Australia) and aimed to further understanding of immunotherapy for advanced solid tumors.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.